OPERA Trial: Use of Omega 3 to prevent post-operative atrial fibrillation

Atrial fibrillation (AF) prolongues post-operative central vascular surgery, increasing morbidity and costs. Though smaller, a few trials have shown positive results for Omega-3 fatty acids. This multi-center trial randomized 1516 patients scheduled for cardiac surgery to receive Omega 3 or placebo. Primary end point was occurrence of AF. Follow up didn’t show difference between Omega 3 and placebo (30% vs. 30,7%; P=0,74).

Conclusion: This trial does not support the use of Omega 3 fatty acids to prevent AF occurrence.

Comment: From the point of view of physiopathology, the anti inflammatory effect of Omega 3 suggested it could be useful in this context. However, though larger than previous studies, the OPERA trial does not support this hypothesis.

2_roberto_marchioli_articulo
Roberto Marchioli
2012-11-05

Original title: Fish Oil for the Prevention of Post-Operative Atrial Fibrillation – The Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) .  

More articles by this author

PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.

Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized double blind placebo controlled trial to evaluate...

GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.

Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are statin intolerant or present adverse effects at...

DALCETRAPIB: Dalcetrabib for the treatment of ACS

High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased HDL 30% from baseline. The objective was...

Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.

Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite the maximal dose or because of adverse...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroSMR Registry: Edge-to-Edge Mitral Treatment with 5-Year Outcomes

Cardiomyopathies and left atrial enlargement can lead to secondary mitral regurgitation (SMR). This condition is associated with ventricular dysfunction, causing heart failure, hospitalization, and...

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...